Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ADB115
- Development stage
- Preclinical
- Lead developer
- AIDEA PHARMA
- Modality
- Small Molecules
- Administration
- Intravenous, Oral
01
Overview
ADB115 is a small molecule therapeutic candidate being developed by Jiangsu Aidi Pharmaceutical (also known as Aidea Pharma) for the treatment of acute peritonitis. It functions as an antagonist of the P2X7 receptor (P2X7 purinoceptor), an ATP-gated ion channel that plays a critical role in the activation of the NLRP3 inflammasome and the subsequent release of pro-inflammatory cytokines such as IL-1β and IL-18. By inhibiting P2X7-mediated signaling, ADB115 is intended to mitigate the severe inflammatory response and tissue damage associated with peritonitis. The drug is currently in the IND-enabling (preclinical) stage of development.
02
Targets
P2RX7 (P2X purinoceptor 7)
Beyond the preview
Go deeper on ADB115.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ADB115.